Literature DB >> 2526419

Effect of timing of hepatitis B vaccine doses on response to vaccine in Yucpa Indians.

S C Hadler1, M A de Monzon, D R Lugo, M Perez.   

Abstract

In a large hepatitis B prevention programme, hepatitis B vaccine was given in standard doses to greater than 1000 susceptible Yucpa Indians between 1983 and 1985. Thirteen months after the programme began, 373 vaccine recipients were tested using commercial radioimmunoassay to titre antibody response to the vaccine. Because of logistic difficulties, only 32% had received vaccine by the recommended schedule (second and third doses at one and six months after the first, respectively). The second and third doses were received early by 4 and 31%, respectively, and 27 and 16% received these doses later than intended. Overall response to vaccine was excellent: 98% of vaccinees developed anti-HBs greater than 10 mIU (geometric mean titre 688 mIU). Multivariate analysis showed that the response to vaccination was inversely related to the age of the vaccinee and directly related to the timing of the third vaccine dose. In particular, those receiving the third vaccine dose late (greater than 7 months after the first dose) developed antibody titres two-fold higher than those receiving the third dose on schedule (p less than 0.01). The response to vaccination was not significantly related to the timing of the second dose. A satisfactory response was obtained with various schedules of dose timing, including early second and third doses, late second and third doses and late second but normal third doses. These findings suggest that the response to hepatitis B vaccine is not highly dependent on timing of vaccine doses and that modest alterations in timing of doses, such as those necessary to integrate hepatitis B vaccine with other childhood vaccines, do not affect the excellent response to this vaccine.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2526419     DOI: 10.1016/0264-410x(89)90046-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Optimal vaccination program for healthy adults in China.

Authors:  Jun Yao; Yan Qiu; Yongdi Chen; Zhenggang Jiang; Lingzhi Shen; Huan Shan; Xuewei Dai; Qian Li; Ying Liu; Wen Ren; Jingjing Ren
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Comparison of the effect of two different doses of recombinant hepatitis B vaccine on immunogenicity in healthy adults.

Authors:  Jing Li; Jun Yao; Huan Shan; Yongdi Chen; Zheng-gang Jiang; Jing-jing Ren; Kai-jin Xu; Bing Ruan; Shi-gui Yang; Bing Wang; Tian-sheng Xie; Qian Li
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 3.  Strategy vaccination against Hepatitis B in China.

Authors:  Xueyan Liao; Zhenglun Liang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Risk of hepatitis B infection among young injection drug users in San Francisco: opportunities for intervention.

Authors:  K H Seal; K C Ochoa; J A Hahn; J P Tulsky; B R Edlin; A R Moss
Journal:  West J Med       Date:  2000-01

5.  Immune response to an indigenously developed r-hepatitis B vaccine in mixed population: study of an accelerated vaccination schedule.

Authors:  A Chowdhury; A Santra; C-M Habibullah; A-A Khan; J Karunakaramaiah; T-S-A Kishore; A-V-R Raju; S Lahiri
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

6.  Routine hepatitis B vaccination in a clinic for sexually transmitted diseases.

Authors:  H S Weinstock; G Bolan; J S Moran; T A Peterman; L Polish; A L Reingold
Journal:  Am J Public Health       Date:  1995-06       Impact factor: 9.308

7.  Randomized controlled trial of two dosing schedules for human papillomavirus vaccination among college age males.

Authors:  Chyongchiou Jeng Lin; Richard K Zimmerman; Mary Patricia Nowalk; Hsin-Hui Huang; Jonathan M Raviotta
Journal:  Vaccine       Date:  2013-12-14       Impact factor: 3.641

8.  Immunogenicity of recombinant hepatitis B vaccine: comparison of two different vaccination schedules.

Authors:  S Agladioglu; U Beyazova; A D Camurdan; F Sahin; A Atak
Journal:  Infection       Date:  2010-05-29       Impact factor: 3.553

9.  T cell mediated immunity induced by the live-attenuated Shigella flexneri 2a vaccine candidate CVD 1208S in humans.

Authors:  Franklin R Toapanta; Paula J Bernal; Karen L Kotloff; Myron M Levine; Marcelo B Sztein
Journal:  J Transl Med       Date:  2018-03-13       Impact factor: 5.531

10.  Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children.

Authors:  Seth Owusu-Agyei; Daniel Ansong; Kwaku Asante; Sandra Kwarteng Owusu; Ruth Owusu; Naana Ayiwa Wireko Brobby; David Dosoo; Alex Osei Akoto; Kingsley Osei-Kwakye; Emmanuel Asafo Adjei; Kwadwo Owusu Boahen; Justice Sylverken; George Adjei; David Sambian; Stephen Apanga; Kingsley Kayan; Johan Vekemans; Opokua Ofori-Anyinam; Amanda Leach; Marc Lievens; Marie-Ange Demoitie; Marie-Claude Dubois; Joe Cohen; W Ripley Ballou; Barbara Savarese; Daniel Chandramohan; John Owusu Gyapong; Paul Milligan; Sampson Antwi; Tsiri Agbenyega; Brian Greenwood; Jennifer Evans
Journal:  PLoS One       Date:  2009-10-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.